Journals / Turkish Journal of Immunology / 2018 / Cilt: 6 - Sayı: 3

The Effect of Intranasal Immunization with Streptococcus Pilus Protein on Nasopharyngeal pIgR and IgA Expression in Rats

Sıçanlarda Streptococcus Pilus Proteini ile İntranazal Bağışıklamanın Nazofaringeal pIgR ve IgA İfadesi Üzerine Etkisi

Pages
87–94
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

TGF-β1, IL-17A, and s-IgA were measured by ELISA while pIgR was examined by immunohistochemistry.Results: This study demonstrated that intranasal immunization with antigen (54 kDa pili protein) and antigen plusadjuvant significantly increased (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: Streptococcus pneumoniae (S. pneumoniae) causes pneumococcal disease, which has high mortality andmorbidity in children under two years of age, the elderly and immunocompromised individuals.
📊
Key Findings & Data:This disease can beprevented by immunization, but the current vaccine, pili protein vaccine (PPV), is less likely to protect children underthe age of two and only protects against the serotypes contained in the vaccine.
💡
Conclusion & Impact:TGF-β1, IL-17A, and s-IgA were measured by ELISA while pIgR was examined by immunohistochemistry.Results: This study demonstrated that intranasal immunization with antigen (54 kDa pili protein) and antigen plusadjuvant significantly increased (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Introduction: Streptococcus pneumoniae (S. pneumoniae) causes pneumococcal disease, which has high mortality andmorbidity in children under two years of age, the elderly and immunocompromised individuals. This disease can beprevented by immunization, but the current vaccine, pili protein vaccine (PPV), is less likely to protect children underthe age of two and only protects against the serotypes contained in the vaccine. Hence, a new vaccine is needed to enablefull protection. The use of bacterial pili proteins may offer an alternative new vaccine. Therefore, the determination ofthe ability of such proteins to stimulate mucosal immunity with indicator expression of pIgR and s-IgA is required.Materials and Methods: Pili were isolated using the pili bacterial cutter method, and used for nasal vaccination tothe rats. TGF-β1, IL-17A, and s-IgA were measured by ELISA while pIgR was examined by immunohistochemistry.Results: This study demonstrated that intranasal immunization with antigen (54 kDa pili protein) and antigen plusadjuvant significantly increased (p

Özet

Giriş: İnfeksiyonlara yol açan Streptococcus pneumoniae (S. pneumoniae) iki yaşın altındaki bebeklerde, yaşlı ve immün yetmezliği olan hastalarda yüksek morbidite ve ölüm oranlarına neden olur. Bu hastalık, aşılama ile önlenebilir, ancak, pili proteini aşısı, 2 yaşın altındaki çocuklarda daha az koruma sağlar ve sadece aşıdaki serotiplere karşı koruma sağlar. Bu neden ile, tam bir koruma sağlayabilecek yeni bir aşıya gerek bulunmaktadır. Anlamlı belirteçler olan pIGR ve sIgA salgılanmasını sağlayarak mukozadaki bağışıklığı oluşturabilecek proteinlere gereksinim vardır. Gereç ve Yöntemler: Pililer, bakterinin pilusunu kesen metod kullanılarak elde edildi ve sıçanların burnundan bağışıklama için kullanıldı. TGF-β1, IL-17A ve sIgA, ELISA metodu ile, pIgR ise, immünohistokimya ile ölçüldü. Bulgular: Bu çalışma, 54kDA’luk pili proteini yapılan aşılama ve protein ile birlikte verilen adjuvanın TGF-β1 ifadesini istatistiksel olarak anlamlı düzeyde (p

🔖

Cite This Article

HANDONO, K., SANTOSO, S., PRAWIRO, S. R., MUFİDA, D. C. (2022). The Effect of Intranasal Immunization with Streptococcus Pilus Protein on Nasopharyngeal pIgR and IgA Expression in Rats. Turkish Journal of Immunology, Cilt: 6 - Sayı: 3, 87–94. https://ajindex.com/articles/607226

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Mitchell AM, Mitchell TJ. Streptococcus pneumoniae: virulence factors and variation. Clin Microbiol Infect 2010
  2. 411–18. [CrossRef] Valenzuela MT, O’Loughlin R, De La Hoz F, Gomez E, Constenla D, Sinha A, et al. The burden of pneumococcal disease among Latin American and Caribbean children: the review of the evidence. Rev Panam Salud Publica 2009
  3. 270–9. [CrossRef] Turner P, Turner C, Sue K, Song S, Ly S, Miliya T, et al. Pneumococcal Infection among Children before Introduction of 13-Valent Pneumococcal Conjugate Vaccine, Cambodia. Emerg Infect Dis 2015
  4. 2080–3. [CrossRef] Feldman C, Anderson R. Current and new generation pneumococcal vaccines. J Infect 2014
  5. 309–25. [CrossRef] Van der Poll T, Opal SM. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet 2009
  6. 1543–56. [CrossRef] Xu, Y, Yuen P, Lam JK. Intranasal DNA vaccine for protection against respiratory infectious diseases: the delivery perspectives. Pharmaceutics 2014
  7. 378–415. [CrossRef] Borsutzky S, Cazac BB, Roes J, Guzman CA. TGF-β receptor signaling is critical for mucosal IgA responses. J Immunol 2004
  8. 3305–9. [CrossRef] Zygmunt BM, Rharbaoui F, Groebe L, Guzman CA. Intranasal Immunization Promotes Th17 Immune Responses. J Immunol 2009
  9. 6933–8. [CrossRef] Jaffar Z, Ferrini ME, Herritt LA, Roberts K. Cutting Edge: Lung mucosal Th17-mediated responses induce polymeric immunoglobulin receptor expression by the airway epithelium and elevate secretory IgA levels. J Immunol 2009
  10. 4507–11. [CrossRef] Cao AT, Yao SY, Gong B, Nelson CO, Cong Y. Th17 cells upregulate polymeric Ig Receptor and Intestinal IgA and Contribute to Intestinal Homeostasis. J Immunol 2012
  11. 4666–73. [CrossRef] Sumarno RP, Susanto A, Ismanoe G, Winarsih. Combinations of protein sub-unit pili 37.8 kDa V.cholerae with cholera toxin sub-unit B V.cholerae can protect come out of the solution in the intestinal mice. J Pharm Biomed Sci 2011
  12. 154–60. Laemmli UK. Cleavage of structural protein during the assembly of the head of bacteriophage T4. Nature 1970
  13. 680–5. [CrossRef] Malley R, Srivastava A, Lipsitch M, Thompson CM, Watkins C, Tzianabos A, Anderson PW. Antibody-independent, interleukin17A-mediated, cross-serotype immunity to Pnuemococci in mice immunized intranasally with cell wall polysaccharide. Infect Immun 2006
  14. 2187–95. [CrossRef] Cai Y, Kurita-Ochiai T, Kobayashi R, Hashizume T, Yamamoto M. Nasal immunization with the 40 kDa outer membrane protein of Porphyromonas ginggival